Stock Market & Financial News
lululemon: I Was Right
lululemon athletica inc. faces intensifying revenue declines, missing Q2 estimates and guiding for its first full-year revenue drop since going public. Americas weakness deepened with 8% revenue and 12% comp sales declines; international growth stalled, notably with China revenues down 2%. Q2 EPS beat was driven by $134.5M in tariff refunds, masking underlying margin and profitability deterioration.
LULU -1.46% Gold Falls Almost $100 on Upbeat US Payrolls Data
Gold fell almost $100 on Friday following surprise surge in US nonfarm payrolls that eased worries of US policymakers and boosted expectations of rate hike on Sep 16 policy meeting.
Panmure Liberum raises Hikma target price to 1,900p
Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker's strong first-half results support further upside in its shares. The broker said Hikma's recent interim results were reassuring, with the only surprises coming on the upside and beats reported across the business.
HKMPF 0% Gold –04.09.2026
Gold hit the target of 4450-72 to break above it. As we see from the chart, the market faces support at the 4440-60 zone, and if prices remain above it, the advance movement could sustain towards the second target at 4545-65.
GBP/USD –04.09.2026
Intraday levels show possible support around 1.3475 which could support the market in the short-term. As we see from the chart, prices face supports at 1.3475 and 1.3400 where each support could lead to an advance toward 1.3675.
USD/JPY –04.09.2026
USDJPY resumed the drop to test the support at 155.00-20 yesterday. As we see over the chart, the support at 155.00-20 could lead to a rebound with resistance at 157.40.
EUR/USD –04.09.2026
The Euro hit a correction towards the target and support of 1.1570. As we see from the chart and as long as the market holds above this support, a rebound towards 1.1710 is likely.
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.
GILD -1.88% 
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
SYK +0.9% 
Airbus: 1,000 Orders, But Deliveries Flash A Warning
Airbus maintains its market leadership with over 1,000 net orders year-to-date, despite ongoing production ramp-up challenges. July deliveries were flat year-on-year at 67 units, with A330 deliveries paused due to a foreign object issue, now resolved. EADSF's book-to-bill ratio remains robust at 2.6x year-to-date, reflecting strong demand and order inflow across both single-aisle and wide-body segments.
EADSF +2.81% 
Adobe stock falls 7% as company announces new CEO amid leadership shakeup
Adobe shares ADBE fell nearly 7% on Friday after the software company announced a leadership transition on Thursday. Anil Chakravarthy, president of Adobe's Customer Experience Orchestration business, will become president and chief executive officer on Dec. 1, 2026.
ADBE -1.48% 
Why I Doubled Down On Credo
Credo grew Q1 revenue 115% to $479 million while sustaining 68% gross margin and 49.3% non GAAP net margin. Management expects FY2027 revenue growth above 85%, with optical revenue exceeding $600 million as a second growth engine emerges. DustPhotonics expands Credo across silicon photonics, 800G, 1.6T and NPO, creating multiple opportunities to increase content per connection.
CRDO +4.03% 
Altcoin Fund Inflows Hit $90 Million: XRP Joins Institutional Rotation
Stevenson cautions that the trend must persist across different market conditions before it can be viewed as a durable shift.
LENZ Therapeutics: Still Speculative But Priced For Disasters
LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited.
LENZ -5.54% 
Gold Weekly Forecast: Fed uncertainty caps the upside
Gold Weekly Forecast: Fed uncertainty caps the upside
UiPath Tumbles 14% as Guided Slowdown Overshadows Revenue Beat
UiPath (NYSE:PATH | PATH Price Prediction) stock is sinking in Friday morning trading after fiscal second-quarter results delivered a headline beat but the forward guide implied a sharp deceleration.
PATH -1.5% 
PayPay: Inorganic Moves To Capture Structural Tailwinds
I initiate coverage of PayPay Corporation (PAYP) with a Buy, after assessing market trends and corporate developments. PAYP's alliance with Seven & i Holdings unlocks significant digital payment adoption potential in an underpenetrated Japanese market. Acquisition of a 70.2% stake in T&D Financial Life Insurance enables PAYP to leverage its 75M user base for cross-selling financial products, as more Japanese re-assess their wealth management options.
PAYP -1.39% 
ZEC Broke $1,000 for the First Time Following Strong Grayscale ZCSH ETF Inflows
Price Surge: ZEC crossed $1,000 and reached $1,021, driven by strong demand and renewed confidence in the privacy‑focused asset. ETF Impact: ZCSH inflows accelerated Zcash's rally, lifting assets under management from $313.5 million to more than $414 million.
Sprinklr (CXM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Sprinklr (CXM) give a sense of how the business performed in the quarter ended July 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CXM -0.38% 
Why Chevron (CVX) is a Top Stock for the Long-Term
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
CVX -0.16% 
Oscar Health, Inc. (OSCR) Just Overtook the 50-Day Moving Average
Oscar Health, Inc. (OSCR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OSCR broke out above the 50-day moving average, suggesting a short-term bullish trend.
OSCR +3.48% 
Is It Worth Investing in Robinhood Markets (HOOD) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
HOOD +1.43% 
Should You Invest in Rigetti Computing (RGTI) Based on Bullish Wall Street Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
RGTI -2.3% 
Brokers Suggest Investing in QuickLogic (QUIK): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
QUIK +1.8% 
Is Emcor Group (EME) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
EME +2.31% 
Wall Street Analysts See Quanta Services (PWR) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
PWR +2.11% 
Is Kroger (KR) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
KR -0.76% 
Brokers Suggest Investing in AppFolio (APPF): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
APPF -0.62% 
Brokers Suggest Investing in Monday.com (MNDY): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
MNDY -1.88% 
Is Archer Aviation (ACHR) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ACHR -2.88% 
